Want to see GB:CRW full AI Analyst Report?
Top Page
Craneware
(LSE:CRW)
Select Model
Select Model
Rating:62Neutral
Price Target:
1,056.00 p
▼(-18.77% Downside)
Action:Reiterated
Date:09/22/26
The score is supported primarily by solid underlying financial quality (low leverage, solid profitability, and strong latest free-cash-flow conversion) and a moderately supportive dividend. It is held back by weak technical momentum (price below all major moving averages with negative MACD) and mixed forward outlook from the earnings call, including a fiscal 2027 revenue reset and uncertainty tied to 340B disruption and cyberattack-related costs.
Positive Factors
Recurring revenue and retention
A substantial recurring revenue base with approximately 100% net revenue retention and customer retention above 90% supports visibility and reduces dependence on new bookings. These characteristics also create opportunities to expand module adoption within established hospital relationships over the next several quarters.
Negative Factors
340B exposure and revenue reset
The fiscal 2027 revenue reset indicates that growth has been deferred while Craneware faces uncertainty in the 340B market. Restrictions on 340B pricing and changing business models may continue to pressure transactional revenue, making near-term growth less predictable despite stable ARR.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue and retention
A substantial recurring revenue base with approximately 100% net revenue retention and customer retention above 90% supports visibility and reduces dependence on new bookings. These characteristics also create opportunities to expand module adoption within established hospital relationships over the next several quarters.
Read all positive factors
Craneware (CRW) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£356.58M
Dividend Yield3.2%
Average Volume (3M)237.30K
Price to Earnings (P/E)25.1
Beta (1Y)0.85
Revenue Growth-3.45%
EPS Growth-1.68%
CountryUK
Employees765
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.56
Shares Outstanding34,384,640
10 Day Avg. Volume73,404
30 Day Avg. Volume237,304
Financial Highlights & Ratios
PEG Ratio8.62
Price to Book (P/B)1.95
Price to Sales (P/S)3.02
P/FCF Ratio14.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£1,600.00Price Target Upside23.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.8
Revenue Forecast (FY)£186.21M
Craneware Business Overview & Revenue Model
Company Description
Craneware plc, with its associated entities, is dedicated to creating, distributing, and maintaining cutting-edge software applications tailored for the U.S. healthcare industry. Its extensive suite of products is designed to streamline and improv...
How the Company Makes Money
Craneware makes money primarily by licensing and providing access to its healthcare software solutions and by delivering associated services that support implementation, optimization, and ongoing customer use.
Key revenue streams typically includ...
Craneware Earnings Call Summary
Earnings Call Date:Sep 21, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Mar 08, 2027
Earnings Call Sentiment Neutral
The call had a mixed but cautiously constructive tone. Management emphasized strong ARR, customer retention, cash generation, liquidity, long-term customer relationships, continued product investment, and customer support following the cyber incident. However, these positives were offset by revenue growth falling below expectations, the fiscal 2027 revenue reset to approximately $185 million, 340B-related transactional revenue pressure, lower gross margin, cybersecurity-related data exposure and unknown costs, and continued regulatory uncertainty. Management expects a return to growth and 30% plus margins in fiscal 2028, but fiscal 2027 is positioned as a transition year.Positive Updates
Resilient Recurring Revenue Base
Annual recurring revenue remained steady at $185 million, recurring revenue was $185 million, net revenue retention was approximately 100%, and customer retention was greater than 90% by all measures.
Negative Updates
Fiscal 2026 Results Below Expectations
Management said it was deeply disappointed by the fiscal 2026 results and acknowledged that the financial outcome, particularly revenue growth, was below expectations.
Read all updates
Q4-2026 Updates
Positive
Negative
Resilient Recurring Revenue Base
Annual recurring revenue remained steady at $185 million, recurring revenue was $185 million, net revenue retention was approximately 100%, and customer retention was greater than 90% by all measures.
Read all positive updates
Company Guidance
For fiscal year ’27, Craneware reset revenue expectations to approximately the level of current ARR, with $185 million as the starting ARR and expected fiscal year ’27 ARR of $185 million; the company is still modeling approximately 100% NRR and is not expecting a drop in ARR. The cost review will be ongoing through the course of this year, with margins not expected to return to 30% plus by the end of this calendar year, but tracking somewhere in the mid- to high 20% margins, while the exit run rate by the end of fiscal ’27 is expected to be aligned to take the company into a 30% plus margin for fiscal ’28. The company expects to return to growth at least into fiscal ’28 and to return to far more positive margins by fiscal ’28, while the cost of the cyberattack remains too hard to quantify and its full impact may take a number of periods, so may extend into future financial years.Craneware Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
80
Positive
Cash Flow
70
Positive
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 206.47M | 205.66M | 189.27M | 174.02M | 165.54M |
| Gross Profit | 138.75M | 179.27M | 162.20M | 148.44M | 142.37M |
| EBITDA | 62.26M | 58.61M | 54.26M | 51.60M | 47.54M |
| Net Income | 19.78M | 19.66M | 11.70M | 9.23M | 9.41M |
Balance Sheet | |||||
| Total Assets | 524.46M | 551.06M | 543.65M | 576.98M | 568.79M |
| Cash, Cash Equivalents and Short-Term Investments | 55.10M | 55.92M | 34.59M | 78.54M | 47.16M |
| Total Debt | 46.77M | 31.65M | 40.15M | 86.69M | 115.52M |
| Total Liabilities | 204.14M | 213.50M | 215.06M | 249.13M | 235.77M |
| Stockholders Equity | 320.31M | 337.56M | 328.59M | 327.84M | 333.02M |
Cash Flow | |||||
| Free Cash Flow | 42.26M | 59.41M | 24.91M | 83.20M | 12.93M |
| Operating Cash Flow | 42.74M | 59.90M | 41.86M | 98.75M | 26.96M |
| Investing Cash Flow | -17.40M | -13.98M | -15.81M | -15.34M | -307.32M |
| Financing Cash Flow | -26.44M | -24.58M | -70.00M | -53.28M | 91.90M |
Craneware Technical Analysis
Negative
1300.00
Price Trends
1173.76
Negative
1223.06
Negative
1356.29
Negative
Market Momentum
-20.04
Negative
37.34
Neutral
15.38
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CRW, the sentiment is Negative. The current price of 1300 is above the 20-day moving average (MA) of 1087.10, above the 50-day MA of 1173.76, and below the 200-day MA of 1356.29, indicating a bearish trend. The MACD of -20.04 indicates Negative momentum. The RSI at 37.34 is Neutral, neither overbought nor oversold. The STOCH value of 15.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CRW.
Craneware Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | £69.14M | 11.52 | 17.74% | ― | -6.51% | 108.62% | |
62 Neutral | £356.58M | 25.05 | 5.94% | 3.20% | -3.45% | -1.68% | |
62 Neutral | £172.63M | -635.94 | -0.68% | ― | 20.14% | 82.22% | |
61 Neutral | £25.73M | -5.99 | -16.18% | ― | 13.04% | 15.88% | |
56 Neutral | £269.22M | 156.65 | 0.83% | ― | 14.84% | -15.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | £15.11M | -9.30 | -54.17% | ― | 11.86% | 23.81% |
* Healthcare Sector Average
GB:CRW
Craneware
1,048.00
-1,159.15
-52.52%
GB:COG
Cambridge Cognition Holdings
28.00
-5.00
-15.15%
GB:IXI
IXICO plc
11.75
0.25
2.17%
GB:KOO
Kooth
190.00
58.00
43.94%
GB:DXRX
Diaceutics
203.50
41.00
25.23%
GB:OPT
Optima Health PLC
247.50
46.04
22.85%
Craneware Corporate Events
Regulatory Filings and Compliance
Craneware Audit Chair Susan Nelson Buys Shares, Aligning Further With Investors
Positive
Sep 22, 2026
Craneware plc, a specialist in healthcare financial performance and operational transformation, develops cloud‑based analytics and revenue optimization tools for hospitals and health systems. Its Trisus ecosystem integrates data and intellig...
Business Operations and StrategyStock BuybackDividendsFinancial DisclosuresRegulatory Filings and Compliance
Craneware Holds Earnings Steady, Resets Guidance After Cyber Incident and 340B Headwinds
Positive
Sep 21, 2026
Craneware reported resilient full-year results for FY26, with revenue broadly flat at $206m, annual recurring revenue steady at $185m and adjusted EBITDA up 3%, supported by high operating cash conversion and strong customer retention. The group m...
Business Operations and StrategyFinancial Disclosures
Craneware Sets Dates for FY26 Results and Investor Presentations
Positive
Sep 16, 2026
Craneware plc, a specialist in healthcare financial performance solutions, is preparing to unveil its audited final results for the year ended 30 June 2026. The company, which offers the Trisus cloud ecosystem to unify data and analytics for hospi...
Business Operations and StrategyRegulatory Filings and Compliance
Craneware Reports Contained Cyber Breach With Limited Operational Impact
Negative
Jul 20, 2026
Craneware has disclosed a cyber security incident involving unauthorised access to a subset of its data environment, prompting activation of its incident response plan and the engagement of external cyber security and forensic specialists alongsid...
Other
Craneware CEO Boosts Stake Through Pension Share Purchase
Positive
Jul 6, 2026
Craneware plc reported that the pension scheme of chief executive Keith Neilson purchased 9,074 ordinary shares at 1,102 pence each on 6 July 2026. Following this transaction, Neilson’s total holding stands at 3,223,545 shares, representing ...
Business Operations and Strategy
Craneware Chair Boosts Stake in Healthcare Finance Specialist
Positive
Jul 3, 2026
Craneware plc, a specialist in healthcare financial performance and operational transformation solutions, leverages its Trisus cloud ecosystem to unify data, revenue intelligence and margin analytics for healthcare providers. Its technology suite,...
Business Operations and StrategyFinancial Disclosures
Craneware Flags FY26 Miss as 340B Slowdown Delays Growth
Negative
Jul 3, 2026
Craneware warned that its financial performance for the year to 30 June 2026 will fall short of market expectations, with revenue forecast at US$205–208 million and adjusted EBITDA at US$65–67 million, broadly flat on the prior year. T...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.